BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/27/2019 8:24:36 AM | Browse: 1022 | Download: 1788
 |
Received |
|
2018-12-28 09:14 |
|
Peer-Review Started |
|
2018-12-29 13:07 |
|
To Make the First Decision |
|
2019-02-18 01:42 |
|
Return for Revision |
|
2019-03-05 00:57 |
|
Revised |
|
2019-04-18 14:40 |
|
Second Decision |
|
2019-04-19 07:19 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-04-19 20:06 |
|
Articles in Press |
|
2019-04-19 20:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-25 07:16 |
|
Publish the Manuscript Online |
|
2019-05-27 08:24 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Review |
| Article Title |
Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qing Xie, Jian-Wei Xuan, Hong Tang, Xiao-Guang Ye, Peng Xu, I-Heng Lee and Shan-Lian Hu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shan-Lian Hu, MD, MSc, Professor, School of Public Health, Fudan University, 130 Dong’an Road, Shanghai 200032, China. shanlian_hu_doc@outlook.com |
| Key Words |
Hepatitis C; Value of cure; Sustained virologic response; End stage liver disease; Prevention of transmission; Cost-effectiveness; Patient-reported outcomes |
| Core Tip |
Chronic hepatitis C is a systemic disease that manifests both hepatically and extrahepatically, leading to impaired patient-reported outcomes (PROs) and huge economic burden on the healthcare system and society. Direct acting antivirals are effective hepatitis C therapies that improve PROs and have broad eligible patient populations, good efficacy, few adverse events, and high adherence rates. Sustained virologic response is associated with improved clinical outcomes and increased work productivity. Curative therapies for hepatis C was of substantial societal and economic value because they reduce productivity loss and avoid the management costs associated with advanced liver disease and extrahepatic manifestations. |
| Publish Date |
2019-05-27 08:24 |
| Citation |
Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 |
| URL |
https://www.wjgnet.com/1948-5182/full/v11/i5/421.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v11.i5.421 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
